With increased use of robotic-assisted radical prostatectomy (RARP), surgeons are seeing better patient outcomes and shorter lengths of hospital stay. Ambulatory surgery centers (ASC) permitting discharge within 23 hours have greater clinical efficiency and reduced costs without sacrificing patient outcomes. To identify patients that can safely undergo RARP in an ambulatory setting, we evaluated preoperative patient and system factors associated with reduced length of stay (LOS) following RARP.
INTRODUCTION AND OBJECTIVES:
With increased use of robotic-assisted radical prostatectomy (RARP), surgeons are seeing better patient outcomes and shorter lengths of hospital stay. Ambulatory surgery centers (ASC) permitting discharge within 23 hours have greater clinical efficiency and reduced costs without sacrificing patient outcomes. To identify patients that can safely undergo RARP in an ambulatory setting, we evaluated preoperative patient and system factors associated with reduced length of stay (LOS) following RARP.
METHODS: We conducted a retrospective review of patients undergoing RARP from March 2015-March 2018 at the Ohio State University Wexner Medical Center. Patient demographics, comorbidities, and system factors were summarized with descriptive statistics overall and by LOS group (<24 or !24 hours). Univariable logistic regression was used to assess associations between preoperative patient/system factors and postoperative LOS. Readmission rates, defined as emergency room visit or hospital readmission, were also summarized at 30 and 90 days post-op.
RESULTS: Among the 338 patients included, the average post-operative LOS was 34 hours with 27 patients (8.0%) having LOS <24 hours and 311 (92.0%) patients having LOS !24 hours. Of the patient and system factors examined, private insurance status (OR[2.38, 95% CI: 1.06, 5.71), use of the Xi robot (OR [2.68, 95% CI: 1.18, 6.68), and later surgery order (OR[5.48, 95% CI: 2.16, 13.21) were associated with increased odds of patients having LOS <24 hours. No strong relationship was seen between surgery order and time of discharge, with median discharge time of 1:44 pm (IQR: 12:06pm, 2:52pm) regardless of surgery order. Readmission rates were lower for patients with LOS <24 hours compared to patients with LOS !24 hours at 30 days (7.4% vs. 14.8%) and at 90 days (0.0% vs. 5.1%) post-op.
CONCLUSIONS: Preoperative patient demographic and clinical factors were similar between patients with LOS <24 and !24 hours. Insurance status, robot type and surgery order were found to be associated with reduced LOS, suggesting that success of RARP in an ASC may rely on socioeconomic and system factors. Discharge times were similar despite surgery order, indicating that hospital workflow may also be contributing to LOS. These results suggest that implementation of a clinical care pathway could potentially shorten LOS for patients currently discharged after 24 hours; however, more data and future studies are needed to confirm these findings.
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MP66-19 RACIAL DIFFERENCES IN PATIENT-REPORTED OUTCOMES OF MEN TREATED FOR LOCALIZED PROSTATE CANCER
Pauline Filippou*, Cleo Samuel, Antonia Bennett, Mian Wang, Arlene Chung, Ethan Basch, Ronald Chen, Bryce Reeve, Angela B. Smith, Chapel Hill, NC INTRODUCTION AND OBJECTIVES: Patient reported outcomes (PROs) more accurately capture patient symptoms than physician assessment. Studies have examined racial differences among patients following prostate cancer treatment using a urologic symptomspecific patient reported outcome measure. However, no study has examined racial differences among more generalized patient-reported symptoms of men undergoing prostate cancer treatment. Our objective was to evaluate the racial differences among generalized PROs in men prior to, during and following localized prostate cancer treatment.
METHODS: Men at a single institution who self identified as African American or white and received surgical or radiation treatment for localized prostate cancer were included. Several PRO questionnaires were administered prior to, during, and 3 months following completion of oncologic treatment. Questionnaires included the PROMIS sleep disturbance, fatigue, anxiety, depression, GIconstipation, GI-diarrhea, sexual function and satisfaction profile, and expanded prostate cancer index composite urinary domain. Bivariable analysis was used to determine racial differences between PROs at the different assessment time points.
RESULTS: 48 men were included in our study, of which 21 self identified as African American. Half (n[24) of the cohort was treated with surgery, and the other half with radiation. African American men had significantly higher anxiety and depression scores at baseline and during treatment when compared to white men (p[0.03, p<0.01 and p<0.01, p<0.01 respectively). Overall fatigue scores worsened during and after treatment compared to baseline for both groups, with African American men reporting significantly more fatigue following completion of treatment compared to white men (p[0.04). Overall sleep disturbance did not differ between the two groups, nor at the different time points assessed. Sexual function worsened during and after treatment compared to baseline for both groups, however did not differ between the two groups. EPIC scores did not differ between the two groups at the differing time points.
CONCLUSIONS: Generalized PRO measurement tools identify racial differences in the patient experience not captured by more commonly used urologic PRO assessments. Future studies could further advance our understanding of racial differences in posttreatment recovery, with the potential for improved patient decisionmaking and quality of care. 
